Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer-Reference-Cited by-同舟云学术

Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer

Published:2008-06 Issue:3 Volume:109 Page:359-363
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Lee Hyo-Pyo,Seo Sang-Soo,Ryu Sang-Young,Kim Jong-Hyeok,Bang Yung-Jue,Park Sang-Yoon,Nam Joo-Hyun,Kang Soon-Beom,Lee Kyung-Hee,Song Yong Sang

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference32 articles.

1. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy;Seiden;Gynecol Oncol,2002

2. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer;Huober;J Cancer Res Clin Oncol,2002

3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

4. Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer;Piccart;Int J Gynecol Cancer,2003

5. Trends in five-year survival rates by race and year of diagnosis, 1974–1996;American Cancer Society;Cancer Fact Fig,2001

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer;International Journal of Molecular Sciences;2021-01-27

2. A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer;British Journal of Cancer;2020-09-30

3. Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement;Journal of Gynecologic Oncology;2018

4. Current status of CPT and its analogues in the treatment of malignancies;Phytochemistry Reviews;2015-02-19

5. Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma;Journal of Obstetrics and Gynaecology Research;2013-09-19